← Back to Analyst Consensus 
AGMB Buy
AgomAb Therapeutics NV
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 25, 2026 | Piper Sandler | initiate | — → Overweight | — | 54% |
| Aug 19, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Jul 23, 2026 | B. Riley Securities | initiate | — → Buy | — | 54% |
| Jun 22, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Mar 3, 2026 | Leerink Partners | initiate | — → Outperform | $36 | 51% |
| Mar 3, 2026 | JP Morgan | initiate | — → Overweight | $32 | 55% |
| Mar 3, 2026 | Morgan Stanley | initiate | — → Overweight | $28 | 54% |
Price Target Trend
Mar 26, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days